VISTA inhibits the activity of CD8+ T cells via high expression on MDSCs from AML patients, and its synergistic effect with PD-1 suggests that combined inhibition of VISTA and PD-1 pathways may be a new strategy to enhance AML immunotherapy [169]. Here, PDCD1 is linked to acute myeloid leukemia.